Screener
Madrigal Pharmaceuticals, Inc. MDGL Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$57.94M-37.0% | -$94.39M-28.9% | -$58.58M+1.4% | -$114.19M-6.8% | -$42.28M+72.2% | ||
| $381K+1.1% | $386K+1.8% | $392K+8.0% | $358K+20.1% | $377K+41.2% | ||
| $35.37M+40.6% | $34.02M+62.5% | $25.79M+45.9% | $26.25M+46.7% | $25.16M+3.1% | ||
| —— | -$167.44M-88.4% | -$133.46M-27.7% | —— | -$47.05M+65.1% | ||
| $4.25M— | $3.85M— | —— | $857K+10.0% | $0-100% | ||
| $34.2M-28.5% | $192.19M+17.3% | $27.58M+158% | —— | $47.86M+139% | ||
| $3.11M+78.7% | $2.33M-73.0% | $8.96M-54.7% | $236.65M+3,071% | $1.74M-98.7% | ||
| $60.69M+2,283% | $28.41M-66.0% | —— | $109.5M— | $2.55M— |
FAQ
- Where does Madrigal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
